Literature DB >> 19800297

Effect of bupivacaine on intervertebral disc cell viability.

Ho Lee1, Gwendolyn Sowa, Nam Vo, Gianluca Vadala, Stephen O'Connell, Rebecca Studer, James Kang.   

Abstract

BACKGROUND CONTEXT: Bupivacaine is a local anesthetic commonly used to relieve or control pain in interventional spine procedures. Bupivacaine has been shown to be toxic to articular cartilage, which has similarities to intervertebral disc (IVD) cartilage, raising concern over a potentially negative effect of bupivacaine on the disc.
PURPOSE: To determine bupivacaine's effect on cell viability of IVD cells in vitro and to elucidate whether this is through apoptosis or necrosis. STUDY
DESIGN: In vitro controlled study of bupivacaine effect on cell viability in human and rabbit IVD cells.
SUBJECTS: Rabbit annulus fibrosus (AF) tissue, nucleus pulposus (NP) cells, and knee articular chondrocytes were isolated from New Zealand white rabbits. Human AF and NP cells were isolated from stage 3 to 4 degenerative disc surgical specimens. OUTCOME MEASURES: Cell viability was assessed after exposure to bupivacaine via trypan blue staining or flow cytometry.
METHODS: Annulus fibrosus and NP cells were grown in monolayer and alginate beads, respectively, to simulate their physiologic environment. The cells were then exposed to bupivacaine or saline control at 60 and 120 minutes and examined for cell viability.
RESULTS: Rabbit NP cell death demonstrated a time and dose dependence in response to bupivacaine. In addition, cell death was greater than that observed for articular chondrocytes. Rabbit AF tissue also demonstrated increased cell death in response to bupivacaine exposure. Human NP cells demonstrated time-dependent cell death, with greater necrosis than apoptosis. Annulus fibrosus cells grown in monolayers also resulted in similar effects, with greater necrosis rather than apoptosis.
CONCLUSIONS: Despite its pain relieving properties, bupivacaine decreases cell viability in rabbit and human disc cells in a time-dependent manner. In addition, the changes observed are greater than that seen for articular chondrocytes. This increase in cell death appears to be related to an increase in necrosis rather than apoptosis. Whether bupivacaine exerts similar effects in vivo or how this relates to overall clinical outcome remains to be explored. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19800297     DOI: 10.1016/j.spinee.2009.08.445

Source DB:  PubMed          Journal:  Spine J        ISSN: 1529-9430            Impact factor:   4.166


  12 in total

Review 1.  Diagnostic discography: what is the clinical utility?

Authors:  David A Provenzano
Journal:  Curr Pain Headache Rep       Date:  2012-02

Review 2.  Cell therapy for the degenerating intervertebral disc.

Authors:  Wei Tong; Zhouyu Lu; Ling Qin; Robert L Mauck; Harvey E Smith; Lachlan J Smith; Neil R Malhotra; Martin F Heyworth; Franklin Caldera; Motomi Enomoto-Iwamoto; Yejia Zhang
Journal:  Transl Res       Date:  2016-11-28       Impact factor: 7.012

3.  In vivo effects of bupivacaine and gadobutrol on the intervertebral disc following discoblock and discography: a histological analysis.

Authors:  Patrick Strube; Berit M Pfitzner; Florian Streitparth; Tony Hartwig; Michael Putzier
Journal:  Eur Radiol       Date:  2016-04-16       Impact factor: 5.315

4.  Bupivacaine decreases cell viability and matrix protein synthesis in an intervertebral disc organ model system.

Authors:  Dong Wang; Nam V Vo; Gwendolyn A Sowa; Robert A Hartman; Kevin Ngo; So Ra Choe; William T Witt; Qing Dong; Joon Y Lee; Laura J Niedernhofer; James D Kang
Journal:  Spine J       Date:  2011-02       Impact factor: 4.166

5.  Cytotoxicity of local anesthetics and nonionic contrast agents on bovine intervertebral disc cells cultured in a three-dimensional culture system.

Authors:  Ana V Chee; Jing Ren; Brett A Lenart; Er-Yun Chen; Yejia Zhang; Howard S An
Journal:  Spine J       Date:  2013-11-15       Impact factor: 4.166

6.  No acceleration of intervertebral disc degeneration after a single injection of bupivacaine in young age group with follow-up of 5 years.

Authors:  Seiji Ohtori; Gen Inoue; Sumihisa Orita; Yawara Eguchi; Nobuyasu Ochiai; Shunji Kishida; Kazuki Kuniyoshi; Junichi Nakamura; Yasuchika Aoki; Tetsuhiro Ishikawa; Masayuki Miyagi; Hiroto Kamoda; Miyako Suzuki; Masashi Takaso; Tomoaki Toyone; Gou Kubota; Yoshihiro Sakuma; Yasuhiro Oikawa; Kazuhide Inage; Takeshi Sainoh; Kazuhisa Takahashi
Journal:  Asian Spine J       Date:  2013-09-04

Review 7.  Liposomal extended-release bupivacaine for postsurgical analgesia.

Authors:  Mark Lambrechts; Michael J O'Brien; Felix H Savoie; Zongbing You
Journal:  Patient Prefer Adherence       Date:  2013-09-06       Impact factor: 2.711

8.  Injection of bupivacaine into disc space to detect painful nonunion after anterior lumbar interbody fusion (ALIF) surgery in patients with discogenic low back pain.

Authors:  Seiji Kimura; Seiji Ohtori; Sumihisa Orita; Gen Inoue; Yawara Eguchi; Masashi Takaso; Nobuyasu Ochiai; Kazuki Kuniyoshi; Yasuchika Aoki; Tetsuhiro Ishikawa; Masayuki Miyagi; Hiroto Kamoda; Miyako Suzuki; Yoshihiro Sakuma; Gou Kubota; Yasuhiro Oikawa; Kazuhide Inage; Takeshi Sainoh; Kazuyo Yamauchi; Tomoaki Toyone; Junichi Nakamura; Shunji Kishida; Jun Sato; Kazuhisa Takahashi
Journal:  Yonsei Med J       Date:  2014-03       Impact factor: 2.759

9.  Cytotoxic effects of the radiocontrast agent iotrolan and anesthetic agents bupivacaine and lidocaine in three-dimensional cultures of human intervertebral disc nucleus pulposus cells: identification of the apoptotic pathways.

Authors:  Koji Iwasaki; Hideki Sudo; Katsuhisa Yamada; Manabu Ito; Norimasa Iwasaki
Journal:  PLoS One       Date:  2014-03-18       Impact factor: 3.240

10.  Effects of single injection of local anesthetic agents on intervertebral disc degeneration: ex vivo and long-term in vivo experimental study.

Authors:  Koji Iwasaki; Hideki Sudo; Katsuhisa Yamada; Hideaki Higashi; Takashi Ohnishi; Takeru Tsujimoto; Norimasa Iwasaki
Journal:  PLoS One       Date:  2014-10-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.